Topical delivery of steroids in inflammatory bowel disease

Current Drug Delivery

Volumn 9, Issue 4, 2012, Pages 345-349

  Girlich, C ^a   Scholmerich J ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Inflammatory bowel disease; Steroids

Indexed keywords

BECLOMETASONE; BECLOMETHASONE 17 MONOPROPIONATE; BUDESONIDE; CORTICOSTEROID; DEXAMETHASONE; DRUG METABOLITE; HYDROCORTISONE; MESALAZINE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; STEROID; UNCLASSIFIED DRUG;

ACNE; ADRENAL SUPPRESSION; ALLERGIC RHINITIS; ASTHMA; CROHN DISEASE; DRUG BINDING; DRUG COATING; DRUG EFFICACY; DRUG METABOLISM; ENTERITIS; HIRSUTISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; MOON FACE; PRIORITY JOURNAL; REMISSION; REVIEW; SIDE EFFECT; STOMACH PH; ULCERATIVE COLITIS;

EID: 84863557115     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720112801323071     Document Type: Review

References (51)

1. Würthwein, G.; Rohdewald, P. Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm. Drug Dispos., 1990, 11, 381-394.
2. Daley-Yates, P.T.; Price, A.C.; Sisson, J.R.; Pereira, A.; Dallow, N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br. J. Clin. Pharmacol., 2001, 51, 400-409.
3. Kumana, C.R.; Seaton, T.; Meghji, M.; Castelli, M.; Benson, R.; Sivakumaran, T. Beclomethasone dipropionate enemas for treating inflammatory bowel disease without producing Cushing's syndrome or hypothalamic pituitary adrenal suppression. Lancet, 1982, 1, 579-583.
4. Lipworth, B.J. Systemic adverse effects of inhaled corticosteroid therapy. Arch. Intern. Med., 1999, 159, 941-955.
5. Gionchetti, P.; D'Arienzo, A.; Rizzello, F.; Manguso, F.; Maieron, R.; Lecis, P.E.; Valpiani, D.; Iaquinto, G.; Annese, V.; Balzano, A.; Varoli, G.; Campieri, M.; Italian BDP Study Group. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J. Clin. Gastroenterol., 2005, 39, 291-297.
6. Biancone, L.; Gionchetti, P.; Blanco Gdel, V.; Orlando, A.; Annese, V.; Papi, C.; Sostegni, R.; D'Incà, R.; Petruzziello, C.; Casa, A.; Sica, G.; Calabrese, E.; Campieri, M.; Pallone, F. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis., 2007, 39, 329-337.
7. Manguso, F.; Balzano, A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Alim. Pharmacol. Ther., 2007, 26, 21-29.
8. Rizzello, F.; Gionchetti, P.; Galeazzi, R.; Novelli, G.; Valpiani, D.; D'Arienzo, A.; Manguso, F.; Castiglione, G.; Varoli, G.; Campieri, M. Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study. Adv. Ther., 2001, 18, 261-271.
9. Campieri, M.; Adamo, S.; Valpiani, D.; D'Arienzo, A.; D'Albasio, G.; Pitzalis, M.; Cesari, P.; Casetti, T.; Castiglione, G.N.; Rizzello, F.; Manguso, F.; Varoli, G.; Gionchetti, P. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Alim. Pharmacol. Ther., 2003,17, 1471-1480.
10. Papi, C.; Aratari, A.; Moretti, A.; Mangone, M.; Margagnoni, G.; Koch, M.; Capurso, L. oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. Dig. Dis. Sci., 2010, 55, 2002-7.
11. Tursi, A.; Giorgetti, G.M.; Brandimarte, G.; Elisei, W.; Aiello, F. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study. Med. Sci. Monit., 2006, 12, PI29-32.
12. Jönsson, G.; Aström, A.; Andersson, P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab. Dispos., 1995,23,137-142.
13. Nyman-Pantelidis, M.; Nilsson, A.; Wagner, Z.G.; Borgå, O. Pharmacokinetics and retrograde colonic spread of budesonide enemas in patients with distal ulcerative colitis. Alim. Pharmacol. Ther., 1994, 8, 617-622.
14. Dahlstrom, K.; Edsbacker, S.; Kallen, A. Rectal pharmacokinetics of budesonide. Eur. J. Clin. Pharmacol., 1996, 49, 293-298.
15. Edsbäcker, S.; Andersson, T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin. Pharmacokinet., 2004, 43, 803-821.
16. Greenberg, G.R.; Feagan, B.G.; Martin, F.; Sutherland, L.R.; Thomson, A.B.; Williams, C.N.; Nilsson, L.G.; Persson, T. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N. Engl. J. Med., 1994, 331, 836-841.
17. Herfarth, H.; Gross, V.; Andus, T.; Caesar, I.; Vogelsang, H.; Adler, G.; Malchow, H.; Petri, A.; Gierend, M.; Schölmerich, J.; German/Austrian Budesonide Study Group. Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization. Int. J. Colorectal. Dis., 2004, 19, 147-152.
18. McKeage, K.; Goa, K.L. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults. Drugs, 2002, 62, 2263-2282.
19. Klotz, U.; Schwab, M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev., 2005, 57, 267-279.
20. Lundin, P.; Naber, T.; Nilsson, M.; Edsbäcker, S. Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease. Alim.Pharmacol. Ther., 2001, 15, 45-51.
21. Edsbäcker, S.; Larsson, P.; Bergstrand, M. Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole. Alim. Pharmacol. Ther., 2003,17,403-408
22. Lichtenstein, G.R.; Bengtsson, B.; Hapten-White, L.; Rutgeerts P. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis. Alim. Pharmacol. Ther., 2009, 29, 643-653.
23. Lundin, P.D.; Edsbäcker, S.; Bergstrand, M.; Ejderhamn, J.; Linander, H.; Högberg, L.; Persson, T.; Escher, J.C.; Lindquist, B. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. Alim. Pharmacol. Ther., 2003, 17,85-92.
24. Edsbäcker, S.; Nilsson, M.; Larsson, P. A cortisol suppression doseresponse comparison of budesonide in controlled ileal release capsules with prednisolone. Alim. Pharmacol. Ther., 1999, 13, 219-224.
25. Rodrigues, C.A.; Nabi, E.M.; Spiliadis, C.; McIntyre, P.B.; Phongsathorn, V.; Lennard-Jones, J.E.; Rosen, A.; Willoughby, J.M. Prednisolone absorption in inflammatory bowel disease: correlation with anatomical site and extent. Alim. Pharmacol. Ther., 1987, 1, 391-399.
26. Tanner, A.R.; Halliday, J.W.; Powell, L.W. Serum prednisolone levels in Crohn's disease and coeliac disease following oral prednisolone administration. Digestion, 1981, 21, 310-315.
27. Thomsen, O.O.; Cortot, A.; Jewell, D.; Wright, J.P.; Winter, T.; Veloso, F.T.; Vatn, M.; Persson, T.; Pettersson, E. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N. Engl. J. Med., 1998, 339, 370-374.
28. Rutgeerts, P.; Löfberg, R.; Malchow, H.; Lamers, C.; Olaison, G.; Jewell, D.; Danielsson, A.; Goebell, H.; Thomsen, O.O.; Lorenz- Meyer, H. A comparison of budesonide with prednisolone for active Crohn's disease. N. Engl. J. Med., 1994, 331, 842-845.
29. Gross, V.; Andus, T.; Caesar, I.; Bischoff, S.C.; Lochs, H.; Tromm, A.; Schulz, H.J.; Bär, U.; Weber, A.; Gierend, M.; Ewe, K.; Schölmerich, J. Oral pH-modified release budesonide versus 6- methylprednisolone in active Crohn's disease. German/Austrian Lorenz- Meyer. J. Gastroenterol. Hepatol., 1996, 8, 905-909.
30. Campieri, M.; Ferguson, A.; Doe, W.; Persson, T.; Nilsson, L.G. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut, 1997, 41, 209-214.
31. Bar-Meir, S.; Chowers, Y.; Lavy, A.; Abramovitch, D.; Sternberg, A.; Leichtmann, G.; Reshef, R.; Odes, S.; Moshkovitz, M.; Bruck, R.; Eliakim, R.; Maoz, E.; Mittmann, U. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology, 1998, 115, 835-840.
32. Levine, A.; Weizman, Z.; Broide, E.; Shamir, R.; Shaoul, R.; Pacht, A.; Dinari, G.; On, A.; Weiss, B.; Bujanover, Y. Israeli Pediatric Gastroenterology Association Budesonide Study Group. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr., 2003, 36, 248-252.
33. Escher, J.C.; European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double- blind, controlled, multicentre trial. Eur. J. Gastroenterol. Hepatol., 2004, 16, 47-54.
34. Gross, V.; Andus, T.; Ecker, K.W.; Raedler, A.; Loeschke, K.; Plauth, M.; Rasenack, J.; Weber, A.; Gierend, M.; Ewe, K.; Schölmerich, J. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group. Gut, 1998, 42, 493-496.
35. Greenberg, G.R.; Feagan, B.G.; Martin, F.; Sutherland, L.R.; Thomson, A.B.; Williams, C.N.; Nilsson, L.G.; Persson, T. Oral budesonide as maintenance treatment for Crohn's disease: a placebo- controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology, 1996, 110, 45-51.
36. Ferguson, A.; Campieri, M.; Doe, W.; Persson, T.; Nygard, G. Oral budesonide as maintenance therapy in Crohn's disease - results of a 12-month study. Global Budesonide Study Group. Alim. Pharmacol. Ther., 1998, 12, 175-183.
37. Löfberg R, Rutgeerts P, Malchow H, Lamers, C.; Danielsson, A.; Olaison, G.; Jewell, D.; Thomsen, o.o.; Lorenz-Meyer, H.; Goebell, H.; Hodgson, H.; Persson, T.; Seidegård, C. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut, 1996, 39, 82-86.
38. Cortot, A.; Colombel, J.F.; Rutgeerts, P.; Lauritsen, K.; Malchow, H.; Hamling, J.; Winter, T.; Van Gossum, A.; Persson, T.; Pettersson, E. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. Gut, 2001, 48, 186-190.
39. Hanauer, S.; Sandborn, W.J.; Persson, A.; Persson, T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Alim. Pharmacol. Ther., 2005, 21, 363-371.
40. de Jong, D.J.; Bac, D.J.; Tan, G.; de Boer, S.Y.; Grabowsky, I.L.; Jansen, J.B, Greinwald, R.; Naber, T.H. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission. Neth. J. Med., 2007, 65(9), 339-345.
41. Scheurlen, C, Allgayer, H.; Hardt, M.; Kruis, W. Effect of shortterm topical corticosteroid treatment on mucosal enzyme systems in patients with distal inflammatory bowel disease. Hepatogastroenterology, 1998, 45, 1539-1545.
42. Campieri, M.; Gionchetti, P.; Belluzzi, A.; Brignola, C.; Tabanelli, G.M.; Miglioli, M.; Barbara, L. 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J. Clin. Gastroenterol., 1988, 10, 406-409.
43. Marshall, J.K.; Irvine, E.J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut, 1997, 40, 775-781.
44. Danielsson, A.; Löfberg, R.; Persson, T.; Schioler, R.; Suhr, O.; Willen, R. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand. J. Gastroenterol., 1992, 27, 9-12.
45. Löfberg, R.; Ostergaard-Thomsen, O.; Langholz, E. et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Alim. Pharmacol. Ther., 1994, 8, 623-629.
46. Matzen, P. Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. Scand. J. Gastroenterol., 1991, 26, 1225-1230.
47. Campieri, M.; Gionchetti, P.; Belluzzi, A.; Brignola, C.; Migaldi, M.; Tabanelli, G.M.; Bazzocchi, G.; Miglioli, M.; Barbara, L. Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis. Dig. Dis. Sci., 1987, 32, 67S-70S.
48. Mulder, C.J.; Fockens, P.; Meijer, J.W.; van der Heide, H.; Wiltink, E.H.; Tytgat, G.N. Beclomethasone dipropionate(3mg) versus 5- aminosalicylic acid (2g) versus the combination of both (3mg/2g) as retention enemas in acute ulcerative proctitis. Eur. J. Gastroenterol. Hepatol., 1996, 8, 549-553.
49. Hanauer, S.B.; Robinson, M.; Pruitt, R.; Lazenby, A.J.; Persson, T.; Nilsson, L.G.; Walton-Bowen, K.; Haskell, L.P.; Levine, J.G. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology, 1998, 115, 525-532.
50. Gross, V.; Bar-Meir, S.; Lavy, A.; Mickisch, O.; Tulassay, Z.; Pronai, L.; Kupcinskas, L.; Kiudelis, G.; Pokrotnieks, J.; Kovács, A.; Faszczyk, M.; Razbadauskas, A.; Margus, B.; Stolte, M.; Müller, R.; Greinwald, R.; International Budesonide Foam Study Group. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Alim. Pharmacol. Ther., 2006, 23, 303-312.
51. Brunner, M.; Ziegler, S.; Di Stefano, A.F.; Dehghanyar, P.; Kletter, K.; Tschurlovits, M.; Villa, R.; Bozzella, R.; Celasco, G.; Moro, L.; Rusca, A.; Dudczak, R.; Müller, M. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br. J. Clin. Pharmacol., 2006, 61, 31-38.